M0250 Adm tocilizu covid-19 second
Also known as: COVID tocilizumab second, toci COVID second dose
Administration of tocilizumab for coronavirus disease 2019 (COVID-19), second dose. Continuation of immune modulation therapy for severe COVID-19.
In Plain Language
Second COVID immune therapy; Follow-up anti-inflammatory infusion
Clinical Context
Administered as subsequent dose in hospitalized COVID-19 patients requiring continued immune suppression to prevent acute respiratory distress syndrome.
RVU Information
CPT M0250 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
M-codes cover quality measures and performance reporting. They are used in value-based care programs to track whether specific clinical actions were taken. Documentation must support that the measured action was performed or a valid exclusion applies.
Specialties
Frequently Asked Questions
What is CPT code M0250?
CPT M0250 (Adm tocilizu covid-19 second) is a M Codes code. Administration of tocilizumab for coronavirus disease 2019 (COVID-19), second dose. Continuation of immune modulation therapy for severe COVID-19.
Is M0250 covered by insurance?
M0250 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Administered as subsequent dose in hospitalized COVID-19 patients requiring continued immune suppression to prevent acute respiratory distress syndrome.
When is CPT M0250 used?
Administered as subsequent dose in hospitalized COVID-19 patients requiring continued immune suppression to prevent acute respiratory distress syndrome.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.